StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $29.92 | $28.46 | -4.86% | 0.0M |
| 05-12 | $28.19 | $28.68 | +1.74% | 0.0M |
| 05-13 | $28.98 | $28.70 | -0.97% | 0.1M |
| 05-14 | $28.10 | $28.60 | +1.78% | 0.0M |
| 05-15 | $28.00 | $26.04 | -7.00% | 0.0M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for PRPO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $6.96M | $24.25M | $17.43M | $10.54M |
Operating Income | $-1.43M | $-1.20M | $-1.74M | $-1.68M |
Net Income | $-1.44M | $-363.00K | $-889.00K | $-810.00K |
EPS (Diluted) | $-0.81 | $-0.23 | $-0.57 | $-0.54 |
Total Assets | $20.80M | $21.32M | $21.15M | $18.82M |
Total Liabilities | $6.64M | $6.76M | $7.40M | $6.53M |
Cash & Equivalents | $2.60M | $2.65M | $2.31M | $1.13M |
Free Cash Flow OCF − CapEx | $14.00K | $359.00K | $68.00K | $112.00K |
Shares Outstanding | 1.78M | 1.78M | 1.75M | 1.52M |
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. It focuses on improving cancer diagnostics, particularly hematologic malignancies. Its objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, and Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division and the Products Division.